Stockreport

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in T...

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Business Wire Wed, February 12, 2025 at 2:00 PM GMT+1 9 min read In This Article URGN PRINCETON, N.J., February 12, 2025 BUSINESS WIRE )--UroGen Pharma Ltd. ( [Read more]